ADC Oncology
44 quarters of real-world claims intelligence.
15 approved therapies. 200+ in the pipeline. $43B in M&A. Here's what the data shows.
Press arrow keys, space, or Enter to advance
Conventional chemo broadly targets all rapidly dividing cells. ADCs chemically link a monoclonal antibody to a cytotoxic payload β delivering lethal precision directly to tumor cells.
Meta-analyses show ADCs deliver longer Overall Survival and Progression-Free Survival vs. standard chemotherapy regimens β with no increase in overall toxicity.
From the first FDA approval in 2000 to 15 approved therapies by 2022, the ADC pipeline has become the defining frontier of precision oncology.
The ADC market grew 4,378% from Q1 2015 to Q4 2025. Every day without granular claims intelligence means navigating the fastest-evolving drug class in oncology history β blindfolded.
Targeting, mechanism, cellular impact, survival, and toxicity
| Dimension | Conventional chemotherapy | ADC |
|---|---|---|
| Targeting | Broad cytotoxicity toward rapidly dividing cells β limited tumor selectivity. | Antibody-directed delivery to tumor-associated antigens on cancer cells. |
| Mechanism | Direct cell killing via classic cytotoxic mechanisms (e.g. DNA damage, tubulin disruption). | mAb + linker + payload; binding, internalization, and intracellular payload release. |
| Cellular impact | Affects malignant and healthy proliferating tissues (e.g. marrow, GI mucosa). | Preferential payload delivery to antigen-expressing tumor cells vs. many normal tissues. |
| OS / PFS | Established benchmarks for each indication and line of therapy. | Meta-analyses: often improved OS and PFS vs. standard chemo β without higher overall toxicity in aggregate. |
| Toxicity | Systemic, dose-limiting toxicities (e.g. myelosuppression, GI, neuropathy). | Potentially reduced off-target payload exposure; agent-specific risks (e.g. ocular, ILD) remain important. |
Broad cytotoxicity toward rapidly dividing cells β limited tumor selectivity.
Antibody-directed delivery to tumor-associated antigens on cancer cells.
Direct cell killing via classic cytotoxic mechanisms (e.g. DNA damage, tubulin disruption).
mAb + linker + payload; binding, internalization, and intracellular payload release.
Affects malignant and healthy proliferating tissues (e.g. marrow, GI mucosa).
Preferential payload delivery to antigen-expressing tumor cells vs. many normal tissues.
Established benchmarks for each indication and line of therapy.
Meta-analyses: often improved OS and PFS vs. standard chemo β without higher overall toxicity in aggregate.
Systemic, dose-limiting toxicities (e.g. myelosuppression, GI, neuropathy).
Potentially reduced off-target payload exposure; agent-specific risks (e.g. ocular, ILD) remain important.
Commercial consolidation β Pfizer/Seagen, AstraZeneca/Daiichi, AbbVie, and others drive claim volume as approvals and M&A reshape the landscape. The lines show how each manufacturer's share of ADC claims has evolved quarter by quarter.
The signal: Manufacturer claim share shifts in the same quarter as approvals and acquisitions β IMX data reflects commercial execution before earnings and public reports.
IMX aggregates, normalizes, and delivers U.S. pharmaceutical claims at a depth no other provider matches β anonymized zip-code-level, claim-by-claim, day-by-day, segmented by ADC agent, payer, and patient demographics.
All 50 U.S. states and anonymized zip codes. Real ADC prescribing patterns β from academic cancer centers to community oncology networks, every quarter.
Every approval, every label expansion, every acquisition footprint is visible in the prescribing data.
Enhertu vs. Adcetris vs. Padcev vs. Trodelvy β claims, spend, and share broken out by agent.
Pfizer/Seagen, AstraZeneca/Daiichi, AbbVie β M&A and commercial execution show up in claims first. IMX tracks manufacturer share day by day.
Medicare, commercial, Medicaid, and cash β payment type mix by quarter from oncology claims. IMX tracks every payer segment.
Birth year and gender breakdowns β essential for modeling real-world patient populations behind the trial data.
The full IMX product resolves claim-level fields across identity, geography, economics, payer and plan, clinical coding, operations, and classification.
Analytic theme β representative IMX dictionary fields
| Theme | IMX fields |
|---|---|
| Product identity | manufacturer, drug_generic_name, drug_name, ndc |
| Patient geography | patient_state (aggregated as location in oncology exports) |
| Spend & payment | ingredient_cost_paid, payment_type, charge fields |
| Payer & plan | payer_name, plan_type_description, plan_type |
| Clinical coding | diagnosis_code, procedure_code |
| Workflow & providers | reject_code, daw_code, billing NPI, referring NPI |
| Therapeutic class | usc_class_name, usc_class_code |
This deck uses aggregated columns from the
oncology exports: location, quarter, total_claims, total_charge_amount, manufacturer_claims, drug_claims, manufacturer, drug_name, payment_types, patient_genders, and patient_birth_years_10 β not the full claim-level schema in every figure.
Academic medical centers and NCI-designated cancer centers create massive geographic prescribing clusters. IMX Data maps ADC claim intensity down to the anonymized zip-code level, revealing which regions are ahead of β or behind β the clinical consensus.
Real insight: When Enhertu's HER2-low indication launched, IMX Data showed NE and Mid-Atlantic adoption at 2Γ the national average within one quarter β reflecting dense academic oncology networks before national access reports surfaced.
50 states tracked. Cancer center density drives geographic ADC adoption patterns visible days ahead of national data.
Enhertu's trajectory is the defining signal. The Phase III DESTINY-Breast06 trial showed median PFS >1 year and a 36% reduction in disease progression or death vs. chemotherapy (ORR: 62.6% vs. 34.4%). The Jan 27, 2025 FDA approval for HER2-low/ ultralow breast cancer expanded the eligible population dramatically β visible in claims data the same quarter. AstraZeneca reported $1,176M U.S. product revenue from Enhertu in FY2025 ($2,446M total U.S. in-market; +32% YoY).
Pfizer's $43B Seagen acquisition, AbbVie's ImmunoGen deal, and AstraZeneca/Daiichi's Enhertu dominance are reshaping the landscape. IMX tracks manufacturer claim share and spend quarter by quarter β so you see consolidation in real-world data first.
The signal isn't the level β it's the change. When a manufacturer's share moves after an approval or acquisition, IMX sees it the same quarter. Real-world claims intelligence ahead of earnings and public reports.
ADC patients skew older β Medicare is the dominant payer. Commercial, Medicaid, and government coverage shifts reveal access policy changes before they appear in public reports. IMX tracks payment type mix by quarter from oncology claims.
The signal isn't the level β it's the change. When Medicare share compresses a point or two day-over-day, formulary access is expanding. IMX sees it first.
High-cost oncology ADC therapies produce a wide spread of charge amounts per claim. The interquartile band (P25βP75) captures where half of claims sit; the median is the midpoint, while the mean reflects the upward pull of high-cost tail claims. The scale runs from zero to a headroom above the upper percentiles and mean.
Teal band β interquartile range (middle 50%). Solid bar β median. Dashed line β mean (average) charge.
Why it matters: Benchmarking access programs, benefit design, and out-of-pocket exposure starts with the shape of the claim distribution β not just averages.
The 1940s birth decade leads β consistent with ADC use concentrated in breast cancer and urothelial cancer patient populations. Younger cohort penetration is the key expansion thesis.
Breast cancer ADC use drives the 62.3% female skew. As urothelial, lung, and gastric indications expand (Padcev, Enhertu NSCLC, gastric HER2+), the gender split will rebalance β trackable in IMX demographics before analyst models update.
Why it matters: As Enhertu's HER2-low indication expands the eligible population, demographic shifts are the earliest signal of real-world adoption breadth.
ICD-10-CM Diagnosis Codes Associated with ADC J-codes billable drugs on the claim: J9042 AdcetrisΒ· J9273 TivdakΒ· J9177 PadcevΒ· J9063 ElahereΒ· J9358 Enhertu
(Hover to see diagnosis descriptions)
Chemotherapy and immunotherapy encounter codes often lead volume; oncology-specific neoplasm codes reflect tumor site and stage of care. IMX surfaces the full diagnosis distribution behind ADC utilization β not just drug names.
Why it matters: Labeling and prior-authorization narratives tie to these codes; shifts here precede shifts in prescribing and access.
IMX Data is the early warning system. Every label expansion, every formulary change, every acquisition's prescribing footprint β visible in claims data before it becomes consensus. 44 quarters of proof.
IMX Data delivers the depth behind the headlines.
Every ADC Β Β·Β Every state Β Β·Β Every day.